AstraZeneca尽管有创纪录的利润,却在中国面临对癌症药物征收0.9百万美元的未偿税的潜在罚款。 AstraZeneca faces potential fines in China for $0.9M in unpaid taxes on cancer drugs, despite record profits.

AstraZeneca在中国可能面临罚款,因为其癌症药物、Imfinzi和Imjudo的未缴纳进口税共达90万美元。 AstraZeneca may face fines in China for unpaid import taxes totaling $0.9 million on its cancer drugs, Imfinzi and Imjudo. 如果认定公司负有责任,可处以相当于未付金额五倍的罚款。 If found liable, the company could be fined up to five times the unpaid amount. 尽管如此,AstraZeneca报告2024年金融业绩强劲,总收入增长18%,达到541亿美元,税收前利润增长26%,达到87亿美元,而肿瘤销售增长24%。 Despite this, AstraZeneca reported strong financial performance in 2024, with total revenues rising 18% to $54.1 billion and pre-tax profits up 26% to $8.7 billion, driven by a 24% rise in oncology sales.